Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The challenge of an expanded therapeutic window in pulmonary hypertension

Nature Reviews Cardiology volume 17, pages 195–197 (2020)Cite this article

Subjects

Our understanding of the causes and consequences of pulmonary hypertension is limited. Consequently, its most distinctive forms with the worst prognosis have been the focus for diagnosis and treatment. We highlight the emerging challenge of reframing the prevalence and prognostic implications of pulmonary hypertension, focusing on the optimal therapeutic window to address the high mortality linked to this condition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Relationship between increasing eRVSP and premature all-cause mortality.

References

  1. Galie, N. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67–119 (2016).

    Article  Google Scholar 

  2. Strange, G. et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm. Circ. 3, 89–94 (2013).

    Article  Google Scholar 

  3. Assad, T. R. et al. Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol. 2, 1361–1368 (2017).

    Article  Google Scholar 

  4. Simonneau, G. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. https://doi.org/10.1183/13993003.01913-2018 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Parasuraman, S. et al. Assessment of pulmonary artery pressure by echocardiography—a comprehensive review. Int. J. Cardiol. Heart Vasc. 12, 45–51 (2016).

    PubMed  PubMed Central  Google Scholar 

  6. Kolte, D. et al. Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J. Am. Heart Assoc. 7, e009729 (2018).

    Article  Google Scholar 

  7. Kovacs, G. et al. Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis? Eur. J. Heart Fail. 21, 1057–1061 (2019).

    Article  Google Scholar 

  8. Huston, J. H. et al. Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol. 4, 1112–1121 (2019).

    Article  Google Scholar 

  9. Strange, G. et al. Threshold of pulmonary hypertension associated with increased mortality. J. Am. Coll. Cardiol. 73, 2660–2672 (2019).

    Article  Google Scholar 

  10. Maron, B. A. & Wertheim, B. M. Toward early diagnosis of pulmonary hypertension: lessons from Oz. J. Am. Coll. Cardiol. 73, 2673–2675 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Torrens University Australia, Adelaide, South Australia, Australia

    Simon Stewart

  2. Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa

    Simon Stewart

  3. University of Notre Dame, Fremantle, Western Australia, Australia

    Geoffrey A. Strange & David Playford

Authors
  1. Simon Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey A. Strange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Playford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Stewart.

Ethics declarations

Competing interests

The authors declare no competing interests other than that the National Echocardiography Database of Australia (NEDA) was initially co-funded with industry support (including from Actelion Pharmaceuticals).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stewart, S., Strange, G.A. & Playford, D. The challenge of an expanded therapeutic window in pulmonary hypertension. Nat Rev Cardiol 17, 195–197 (2020). https://doi.org/10.1038/s41569-020-0332-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-020-0332-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing